Sayoko E Moroi1, David M Reed1, David S Sanders1,2,3, Ahmed Almazroa1,4, Lawrence Kagemann5,6,7, Neil Shah8, Nakul Shekhawat1, Julia E Richards1,9. 1. Department of Ophthalmology and Visual Sciences, WK Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan. 2. Department of Ophthalmology, Casey Eye Institute, Oregon Health & Science University. 3. Devers Eye Institute, Legacy Health System, Portland, Oregon, USA. 4. Currently at King Abdullah International Medical Research Center (KAIMRC), King Saud bin Abdulaziz University for Health Science, Ministry of National Guard, Riyadh, Saudi Arabia. 5. Department of Ophthalmology, NYU School of Medicine, New York City, New York. 6. Division of Ophthalmic and Ear, Nose and Throat Devices, Office of Device Evaluation, Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring. 7. Department of Ophthalmology, University of Maryland School of Medicine, Baltimore, Maryland. 8. Department of Ophthalmology, Loyola University Medical Center, Maywood, Illinois. 9. Department of Epidemiology, University of Michigan, Ann Arbor, Michigan, USA.
Abstract
PURPOSE OF REVIEW: Approximately 10% of patients become blind despite using evidence-based guidelines developed from clinical trials and epidemiology studies. Our purpose is to review opportunities to decrease glaucoma-related blindness using the emerging principles of precision medicine. RECENT FINDINGS: The current review focuses on three topics: first, candidate biomarkers for angle-based surgeries, second, head-mounted display (HMD) technology for vision and testing, and third, glaucoma risk alleles discovered by genome-wide association studies. First, in angle-based surgeries, tracers injected into the anterior chamber or Schlemm's canal have allowed visualization of aqueous veins. We describe an innovative use of optical coherence tomography angiography to visualize aqueous veins in a case with 6-year successful outcome following catheter-based trabeculotomy. Second, HMD technology can augment perceived vision and can be used for perimetry testing. Third, developing genetic risk scores that characterize patients who are at highest risk for blindness is a priority. Such biomarker risk scores will integrate genome-wide association study-based risk alleles for glaucoma along with well known demographic and clinical risk factors. SUMMARY: As we gain more knowledge, precision medicine will enable clinicians to decrease glaucoma-related blindness by providing more timely interventions to those patients who are at highest risk for progression to blindness. VIDEO ABSTRACT: http://links.lww.com/COOP/A29.
PURPOSE OF REVIEW: Approximately 10% of patients become blind despite using evidence-based guidelines developed from clinical trials and epidemiology studies. Our purpose is to review opportunities to decrease glaucoma-related blindness using the emerging principles of precision medicine. RECENT FINDINGS: The current review focuses on three topics: first, candidate biomarkers for angle-based surgeries, second, head-mounted display (HMD) technology for vision and testing, and third, glaucoma risk alleles discovered by genome-wide association studies. First, in angle-based surgeries, tracers injected into the anterior chamber or Schlemm's canal have allowed visualization of aqueous veins. We describe an innovative use of optical coherence tomography angiography to visualize aqueous veins in a case with 6-year successful outcome following catheter-based trabeculotomy. Second, HMD technology can augment perceived vision and can be used for perimetry testing. Third, developing genetic risk scores that characterize patients who are at highest risk for blindness is a priority. Such biomarker risk scores will integrate genome-wide association study-based risk alleles for glaucoma along with well known demographic and clinical risk factors. SUMMARY: As we gain more knowledge, precision medicine will enable clinicians to decrease glaucoma-related blindness by providing more timely interventions to those patients who are at highest risk for progression to blindness. VIDEO ABSTRACT: http://links.lww.com/COOP/A29.
Authors: A Bilge Ozel; Sayoko E Moroi; David M Reed; Melisa Nika; Caroline M Schmidt; Sara Akbari; Kathleen Scott; Frank Rozsa; Hemant Pawar; David C Musch; Paul R Lichter; Doug Gaasterland; Kari Branham; Jesse Gilbert; Sarah J Garnai; Wei Chen; Mohammad Othman; John Heckenlively; Anand Swaroop; Gonçalo Abecasis; David S Friedman; Don Zack; Allison Ashley-Koch; Megan Ulmer; Jae H Kang; Yutao Liu; Brian L Yaspan; Jonathan Haines; R Rand Allingham; Michael A Hauser; Louis Pasquale; Janey Wiggs; Julia E Richards; Jun Z Li Journal: Hum Genet Date: 2013-09-04 Impact factor: 4.132
Authors: Frank Brodie; Michael Repka; Stephen Allan Burns; S Grace Prakalapakorn; Christie Morse; Joel S Schuman; Michael R Duenas; Natalie Afshari; John S Pollack; Jennifer E Thorne; Albert Vitale; H Nida Sen; David Myung; Mark S Blumenkranz; Elmer Tu; Daniel X Hammer; Michelle Tarver; Bradley Cunningham; Larry Kagemann; SriniVas Sadda; David Sarraf; Glenn J Jaffe; Malvina Eydelman Journal: JAMA Ophthalmol Date: 2021-01-01 Impact factor: 7.389
Authors: Lev Prasov; Brenda L Bohnsack; Antonette S El Husny; Lam C Tsoi; Bin Guan; J Michelle Kahlenberg; Edmundo Almeida; Haitao Wang; Edward W Cowen; Adriana A De Jesus; Priyam Jani; Allison C Billi; Sayoko E Moroi; Rachael Wasikowski; Izabela Almeida; Luciana N Almeida; Fernando Kok; Sarah J Garnai; Shahzad I Mian; Marcus Y Chen; Blake M Warner; Carlos R Ferreira; Raphaela Goldbach-Mansky; Sun Hur; Brian P Brooks; Julia E Richards; Robert B Hufnagel; Johann E Gudjonsson Journal: J Med Genet Date: 2021-01-25 Impact factor: 6.318
Authors: Maria Jesus Rodrigo; Amaya Pérez Del Palomar; Alberto Montolío; Silvia Mendez-Martinez; Manuel Subias; Maria Jose Cardiel; Teresa Martinez-Rincon; José Cegoñino; José Maria Fraile; Eugenio Vispe; José Antonio Mayoral; Vicente Polo; Elena Garcia-Martin Journal: Pharmaceutics Date: 2021-02-05 Impact factor: 6.321